Next-Generation Sequencing (NGS) has emerged as the defining infrastructure of precision oncology, infectious disease identification, and reproductive genetics. For years, the global genomic sequencing landscape was dominated by Western proprietary instrument monopolies, leaving international diagnostic reference centers and academic pathology laboratories vulnerable to high reagent costs, inflexible flow-cell batching, and supply-chain vulnerabilities. Headquartered with a massive global intelligent manufacturing base in the Shanghai Lingang Special Area, MGI Tech (华大智造) broke this paradigm with its proprietary DNBSEQ™ Sequencing Platforms (including the ultra-rapid DNBSEQ-G99 and the ultra-high-throughput DNBSEQ-T7).
For international hospital laboratory directors, genomic pathology chairs, commercial diagnostic reference chains, and medical device distributors seeking to establish cost-efficient, high-fidelity genetic sequencing capacity, China Medical Concierge – Shanghai (CMCS) acts as your authoritative on-ground procurement navigation and laboratory liaison in Shanghai.
1. Core Clinical Scenarios & DNBSEQ™ Technological Innovations
MGI's sequencing platforms are built on unique biological engineering that differentiates them from conventional PCR-bridge sequencing-by-synthesis:
The DNA Nanoball (DNBSEQ™) Advantage: Zero Optical Duplication
- Rolling Circle Replication (RCR) Amplification: Instead of exponential PCR amplification that accumulates errors and creates index hopping, DNBSEQ uses linear rolling circle replication to form compact DNA Nanoballs (DNBs). Each copy is synthesized directly from the original circular template, ensuring zero accumulation of copying errors.
- High-Density Photolithographic Patterned Arrays: DNBs are loaded onto micro-etched patterned silicon flow cells, ensuring strictly one nanoball per grid point. This produces clean optical signals without index hopping, achieving ultra-high base calling accuracy (Q30 ≥ 85%–90%).
- Lowest Cost per Gigabase (Gb) Globally: Substantially reduces sequencing reagent costs, enabling high-coverage whole-genome and whole-exome sequencing at sustainable reimbursement rates.
Clinical Application Horizons
- Pathogen Metagenomic Next-Generation Sequencing (mNGS): Utilizing the rapid DNBSEQ-G99 (delivering PE150 sequencing data in as fast as 12 hours), clinical microbiology teams can identify bacteria, fungi, viruses, and parasites in a single assay for critically ill ICU patients with unexplained sepsis or encephalitis.
- Comprehensive Genomic Profiling (CGP) in Oncology: Large multigene tumor panels detecting single-nucleotide variants (SNVs), insertions/deletions (InDels), copy number variations (CNVs), structural gene fusions, Tumor Mutational Burden (TMB), and Microsatellite Instability (MSI).
- Rare Disease Genetics & Reproductive Health: Whole Exome Sequencing (WES) for pediatric developmental delays, Non-Invasive Prenatal Testing (NIPT), and Preimplantation Genetic Testing (PGT).
2. Premier Shanghai Academic Institutions Utilizing DNBSEQ™ Systems
Shanghai is home to national clinical research centers for genomics and pediatric genetics that rely daily on MGI DNBSEQ™ instruments:
-
Children's Hospital of Fudan University (复旦大学附属儿科医院)
National Children's Medical Center & Center for Molecular Medicine: An international reference leader in pediatric rare disease diagnosis and neonatal intensive care genomics, pioneering rapid clinical whole-exome sequencing pathways to diagnose critically ill newborns with unexplained genetic conditions. -
Shanghai Ruijin Hospital (Shanghai Jiao Tong University School of Medicine)
State Key Laboratory of Medical Genomics: Renowned for molecular targeted oncology and hematologic malignancies, utilizing high-throughput sequencing to identify novel therapeutic targets and trace molecular residual disease (MRD). -
Shanghai Huashan Hospital (Fudan University)
Department of Infectious Diseases: National Medical Center for Infectious Diseases, pioneering the clinical translation of pathogen mNGS for complex central nervous system and pulmonary infections.
3. Procurement Advantages for Overseas Laboratories & Distributors
- Flexible Sizing from Benchtop to Production Scale: Laboratories can select the compact, ultra-rapid DNBSEQ-G99 (ideal for acute emergency mNGS and targeted panels) or scale up to the industrial powerhouse DNBSEQ-T7 (generating up to 6 Tb of high-quality data per day for national genome projects).
- Freedom from Monopolistic Lock-In: Fully compatible with standardized open-source bioinformatics pipelines, providing laboratories with autonomy over data ownership, library preparation chemistry, and clinical interpretation workflows.
- Comprehensive Global Regulatory Clearances: Certified under China NMPA for diagnostic use, European Union CE-IVD / CE-IVDR, and cleared across international jurisdictions in Europe, the Americas, the Middle East, and Asia-Pacific.
- Automated Sample Preparation Bundles: Available alongside MGI's automated liquid handling workstations (e.g., MGISP-100 / MGISP-960) to provide complete automated sample-to-result sequencing pipelines.
4. How CMCS Assists Overseas Buyers with End-to-End Procurement
Procuring high-throughput genetic sequencers and setting up clinical molecular biology laboratories requires cleanroom design verification, flow-cell chemistry validation, and direct manufacturer contract negotiation. CMCS provides an authoritative bridge in Shanghai:
- Laboratory Workflow Observation & Peer Scientific Exchange: We coordinate on-ground visits to premier genomic medicine laboratories in Shanghai (such as Fudan Children’s Hospital and Huashan Hospital), allowing visiting laboratory directors to observe live library prep, flow-cell loading, and bioinformatics data pipelines alongside Chinese genomic specialists.
- Lingang Intelligent Manufacturing Campus Audits: CMCS organizes guided technical tours of MGI Tech’s state-of-the-art global manufacturing base in the Shanghai Lingang Free Trade Zone, inspecting optical alignment testing lines, flow-cell micro-fabrication cleanrooms, and automated reagent packaging lines.
- Direct Commercial & National Project Negotiations: We connect international buyers directly with MGI Tech’s global commercial leadership and authorized export divisions, securing uninflated factory-direct pricing, bulk flow-cell standing order discounts, and customized application support packages without intermediary markups.
- Bonded Cold-Chain Transit & Regulatory Dossier Support: We coordinate with licensed specialized freight forwarders via the Shanghai Free Trade Zone to ensure temperature-monitored international shipping for enzymes and flow cells, assisting distributors with CE technical files and local health ministry registration dossiers.
Compliance & Regulatory Notice
China Medical Concierge – Shanghai (CMCS) is an independent healthcare management and medical procurement navigation consultancy based in Shanghai. CMCS is not an authorized distributor, manufacturer, or healthcare facility. We facilitate on-ground technical audits, clinical site visits, and commercial communication channels. All commercial sales agreements, volume contracts, regulatory registrations, and product warranties are executed directly between the purchaser and the certified original equipment manufacturer (OEM) or its licensed export trade partners in compliance with international trade laws.
Initiate a Genomic Sequencing Procurement Consultation in Shanghai
To schedule an observation of clinical sequencing workflows in a Shanghai hospital laboratory, coordinate an audit of MGI Tech's Lingang manufacturing base, or receive technical specifications and export pricing packages for DNBSEQ™ Gene Sequencers, please contact our international liaison desk:
- Email: contract@medicalsh.com
- WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
- Website: www.medicalsh.com
0件のコメント